* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, June 8, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

    Ceramic Dalmatian Entertainment is WLAF’s Business of the Week – WLAF

    Spotlight on Success: Ceramic Dalmatian Entertainment Shines as This Week’s Featured Business!

    Brass Lion Entertainment unveils co-op action RPG Wu-Tang: Rise of the Deceiver – VentureBeat

    Unleash Your Inner Warrior: Discover the Co-Op Action RPG Wu-Tang: Rise of the Deceiver!

    Entertainment lineup released for 2025 Mississippi State Fair – WAPT

    Exciting Entertainment Lineup Unveiled for the 2025 Mississippi State Fair!

    After Denzel Washington Said He Would Be In Black Panther 3, Ryan Coogler Explained Why He’s ‘Fine’ With That Information Being Revealed So Early – Yahoo

    Ryan Coogler Shares Why He’s Cool with Denzel Washington’s Black Panther 3 Reveal!

    Traveling Tacos and Tequila Festival to stop at Florence Yall’s stadium this October – Cincinnati Enquirer

    Get Ready for a Flavor Fiesta: Traveling Tacos and Tequila Festival Hits Florence Y’all’s Stadium This October!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Innovation at Scale: How P&G Transforms Business Through Technology – Procter & Gamble

    Revolutionizing Business: P&G’s Bold Journey into Technological Innovation

    Drag racer survives frightening airborne crash at World Wide Technology Raceway – FOX 2

    Drag racer survives frightening airborne crash at World Wide Technology Raceway – FOX 2

    Apple Watch and the future of wearable technology in healthcare – MSN

    Revolutionizing Healthcare: The Future of Wearable Technology with Apple Watch

    ECS Professor Pankaj K. Jha Receives NSF Grant to Develop Quantum Technology – Syracuse University News

    Unlocking the Future: ECS Professor Pankaj K. Jha Secures NSF Grant for Groundbreaking Quantum Technology Development

    Fire Tech Brief: 5 Fire Apparatus Technology Upgrades – firehouse.com

    Revving Up Safety: 5 Innovative Upgrades for Fire Apparatus Technology

    U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 – Sarepta Therapeutics

    Breakthrough for Gene Therapy: FDA Designates Viral Vector in Sarepta’s SRP-9003 for Limb Girdle Muscular Dystrophy Treatment

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

    Ceramic Dalmatian Entertainment is WLAF’s Business of the Week – WLAF

    Spotlight on Success: Ceramic Dalmatian Entertainment Shines as This Week’s Featured Business!

    Brass Lion Entertainment unveils co-op action RPG Wu-Tang: Rise of the Deceiver – VentureBeat

    Unleash Your Inner Warrior: Discover the Co-Op Action RPG Wu-Tang: Rise of the Deceiver!

    Entertainment lineup released for 2025 Mississippi State Fair – WAPT

    Exciting Entertainment Lineup Unveiled for the 2025 Mississippi State Fair!

    After Denzel Washington Said He Would Be In Black Panther 3, Ryan Coogler Explained Why He’s ‘Fine’ With That Information Being Revealed So Early – Yahoo

    Ryan Coogler Shares Why He’s Cool with Denzel Washington’s Black Panther 3 Reveal!

    Traveling Tacos and Tequila Festival to stop at Florence Yall’s stadium this October – Cincinnati Enquirer

    Get Ready for a Flavor Fiesta: Traveling Tacos and Tequila Festival Hits Florence Y’all’s Stadium This October!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Innovation at Scale: How P&G Transforms Business Through Technology – Procter & Gamble

    Revolutionizing Business: P&G’s Bold Journey into Technological Innovation

    Drag racer survives frightening airborne crash at World Wide Technology Raceway – FOX 2

    Drag racer survives frightening airborne crash at World Wide Technology Raceway – FOX 2

    Apple Watch and the future of wearable technology in healthcare – MSN

    Revolutionizing Healthcare: The Future of Wearable Technology with Apple Watch

    ECS Professor Pankaj K. Jha Receives NSF Grant to Develop Quantum Technology – Syracuse University News

    Unlocking the Future: ECS Professor Pankaj K. Jha Secures NSF Grant for Groundbreaking Quantum Technology Development

    Fire Tech Brief: 5 Fire Apparatus Technology Upgrades – firehouse.com

    Revving Up Safety: 5 Innovative Upgrades for Fire Apparatus Technology

    U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 – Sarepta Therapeutics

    Breakthrough for Gene Therapy: FDA Designates Viral Vector in Sarepta’s SRP-9003 for Limb Girdle Muscular Dystrophy Treatment

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

New Trials in Lung Cancer: Could Your Patients Benefit?

June 25, 2024
in Health
New Trials in Lung Cancer: Could Your Patients Benefit?
Share on FacebookShare on Twitter

Several new studies in lung cancer have opened their doors recently. Is one of your patients eligible to participate?

Resected stage II, IIIA, or IIIB with nodal involvement non–small cell lung cancer (NSCLC). Adult patients with this type of cancer can join a randomized, controlled, phase 3 study assessing whether an investigational drug called V940 added to pembrolizumab (Keytruda) delays cancer recurrence better than pembrolizumab alone.

V940 is an individualized neoantigen therapy designed to generate T-cell antitumor responses targeted to a patient’s specific mutation profile.

V940 plus pembrolizumab showed a trend toward longer recurrence-free survival vs pembrolizumab alone in a recent phase 2 study in melanoma (hazard ratio, 0.561; P=.053).

In the current trial, one group of participants will receive intramuscular injections of V940 every 3 weeks plus intravenous (IV) pembrolizumab every 6 weeks for up to approximately 1 year or until disease recurrence or unacceptable toxicity, whichever happens first. The other people in the trial will be on the same schedule, with a placebo replacing V940.

Centers in Florida, Georgia, Kentucky, Montana, New Jersey, New York, North Dakota, and six other countries started recruiting for the trial’s 868 participants in December 2023. Disease-free survival is the primary endpoint. Overall survival over approximately 12 years and quality of life (QoL) are secondary endpoints. More details at clinicaltrials.gov

Metastatic NSCLC with a programmed cell death ligand 1 (PD-L1)-tumor proportion score of > 50%. Adults in this clinical situation are eligible for a randomized, open-label, phase 3 trial to determine whether an experimental antibody-drug conjugate called MK-2870 added to standard pembrolizumab prolongs survival.

MK-2870 delivers a cytotoxin to cancer cells by binding to trophoblast cell-surface antigen 2, known to promote tumor cell growth and metastasis. For up to 2 years, half of participants will receive MK-2870 by IV every 2 weeks plus IV pembrolizumab every 6 weeks. The other group will receive only pembrolizumab.

In December 2023, study sites in Georgia, Minnesota, Mississippi, Nevada, Oregon, Australia, Denmark, Taiwan, and Turkeystarted seeking the trial’s 614 participants. Overall survival over approximately 4 years is the primary endpoint; QoL is a secondary endpoint. More details at clinicaltrials.gov

Untreated locally advanced or metastatic NSCLC with KRAS G12C mutations. Individuals with this type of lung cancer may be interested in a randomized, controlled, phase 3 study examining whether an experimental oral KRAS G12C inhibitor called LY3537982 boosts the effectiveness of standard treatment and patients can tolerate the combination. Currently approved KRAS G12C inhibitors sotorasib (Lumakras, Lumykras) and adagrasib (Krazati) are indicated for second-line treatment; this trial may lead to a first-line approval for newcomer LY3537982.

The trial has three parts: Dose optimization, safety, and efficacy. During dose optimization, each participant will take one of two oral doses of LY3537982 and receive IV pembrolizumab every 3 weeks. In the safety phase, all participants will receive oral LY3537982 at the chosen dose plus standard therapy of 3-weekly IV pembrolizumab, pemetrexed, and a platinum therapy (cisplatin or carboplatin). In the experimental phase, for up to about 1 year, participants will receive one of these four options: Pembrolizumab plus LY3537982, pembrolizumab plus a placebo, standard therapy plus LY3537982, or standard therapy plus a placebo.

The study, which is planning to recruit 1016 participants, opened across 16 US states and 12 countries worldwide in December 2023. Sites in 11 more US states, the District of Columbia, Brazil, Canada, China, India, and 11 more European countries are gearing up. Adverse events and progression-free survival are the primary endpoints. Overall survival over approximately 3 years and QoL are secondary endpoints. More details at clinicaltrials.gov

Unresectable, untreated locally advanced or metastatic non-squamous NSCLC with human epidermal growth factor receptor 2 (HER2) mutations. People with this diagnosis who have HER2 mutations instead of KRAS G12C mutations can participate in a phase 3 study comparing an investigational oral first-line treatment with standard IV therapy. The drug in this study zongertinib is a HER2 tyrosine kinase inhibitor.

For up to approximately 4 years, one group of participants will take oral zongertinib only, and the other individuals will receive IV pembrolizumab, pemetrexed, and a platinum agent (cisplatin or carboplatin). Study sites in California, Missouri, South Carolina, Australia, China, Japan, South Korea, and Singapore opened in January ready to welcome 270 participants. Progression-free survival is the primary outcome. Overall survival over 53 months and QoL are secondary endpoints. More details at clinicaltrials.gov

Completely resected stage IIB, IIIA, or select IIIB, PD-L1–positive NSCLC. Adults with this type of lung cancer who have received adjuvant platinum-based chemotherapy may be eligible for a randomized, controlled, phase 3 study to assess whether two immune checkpoint inhibitors are better than one at delaying cancer recurrence. In this trial, tiragolumab will be added to the approved PD-L1 inhibitor atezolizumab (Tecentriq).

A recent study, however, found that tiragolumab did not confer an additional benefit when added to atezolizumab, carboplatin, and etoposide in untreated extensive-stage small-cell lung cancer.

In the current trial, one group of participants will receive IV atezolizumab and tiragolumab, while the other people will receive a placebo instead of tiragolumab. Centers in California, Georgia, Illinois, New Mexico, Australia, China, South Korea, and Taiwan started recruiting for the trial’s 1150 participants in March 2024. Disease-free survival is the primary endpoint. Overall survival over approximately 15 years and QoL are secondary outcomes. More details at clinicaltrials.gov

Previously treated metastatic or non-operable non-squamous NSCLC. Adults in this position who have received no more than one platinum-based chemotherapy and one anti–PD-L1 drug are sought for a randomized, open-label, phase 3 trial comparing second-line standard docetaxel with experimental antibody-drug conjugate sigvotatug vedotin. Patients who have tumors with certain treatable genomic alterations must have received at least one drug targeted to that alteration, as well as a platinum-based agent.

Approximately half the participants will receive sigvotatug vedotin by IV every 2 weeks, and the other half will receive IV docetaxel every 3 weeks. The study opened in March across 13 US states, France, Hungary, Poland, and Spain seeking 600 people eligible to participate. The primary outcomes are overall survival over approximately 5 years and objective response rate. QoL is a secondary outcome. More details at clinicaltrials.gov

All trial information is from the National Institutes of Health US National Library of Medicine (online at clinicaltrials.gov).

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/new-trials-lung-cancer-could-your-patients-benefit-2024a1000bo9

Tags: CancerhealthTrials
Previous Post

High Recurrence in Acute Uveitis Linked to Viral Causes

Next Post

How we can slow down or prevent Alzheimer’s

Shotgun sequencing of airborne eDNA achieves rapid assessment of whole biomes, population genetics and genomic variation – Nature

Revolutionizing Biodiversity: Rapid Insights into Ecosystems and Genetic Diversity Through Shotgun Sequencing of Airborne eDNA

June 8, 2025
Earth’s energy balance is rising much faster than scientists predicted, and we have no idea why – Live Science

Unraveling the Mystery: Earth’s Energy Balance is Surging Faster Than Expected!

June 8, 2025
The Undermining of Science — and Society — Continues – UExpress

How the Erosion of Science is Impacting Our Society

June 8, 2025
10 habits that secretly ‘kill’ your happy hormones – Times of India

10 Surprising Habits That Sabotage Your Happy Hormones

June 8, 2025
A GPS Blackout Would Shut Down the World – WIRED

How a GPS Blackout Could Bring the World to a Standstill

June 8, 2025
Six Steps To Ruin a Country’s Image, Economy, and Global Standing | Opinion – Newsweek

Six Surefire Ways to Dismantle a Nation’s Reputation and Prosperity

June 8, 2025
Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

Exciting Updates from the Middle Eastern Entertainment Scene!

June 8, 2025
Omada shares rise 21% in Nasdaq debut after health tech company’s IPO – CNBC

Omada Soars 21% in Thrilling Nasdaq Debut Following Successful IPO!

June 8, 2025
Politics-Based Investing Sounds Smart. But These Strategies Work Better. – Barron’s

Politics-Based Investing Sounds Smart. But These Strategies Work Better. – Barron’s

June 8, 2025
Innovation at Scale: How P&G Transforms Business Through Technology – Procter & Gamble

Revolutionizing Business: P&G’s Bold Journey into Technological Innovation

June 8, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (677)
  • Economy (690)
  • Entertainment (21,596)
  • General (15,271)
  • Health (9,732)
  • Lifestyle (694)
  • News (22,149)
  • People (691)
  • Politics (698)
  • Science (15,909)
  • Sports (21,193)
  • Technology (15,676)
  • World (675)

Recent News

Shotgun sequencing of airborne eDNA achieves rapid assessment of whole biomes, population genetics and genomic variation – Nature

Revolutionizing Biodiversity: Rapid Insights into Ecosystems and Genetic Diversity Through Shotgun Sequencing of Airborne eDNA

June 8, 2025
Earth’s energy balance is rising much faster than scientists predicted, and we have no idea why – Live Science

Unraveling the Mystery: Earth’s Energy Balance is Surging Faster Than Expected!

June 8, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version